The University of Chicago Header Logo

Connection

Bruce Brockstein to Head and Neck Neoplasms

Back to Details
This is a "connection" page, showing publications Bruce Brockstein has written about Head and Neck Neoplasms.
Bruce Brockstein
Connection Strength
4.317
Head and Neck Neoplasms
  1. Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma. Arch Pathol Lab Med. 2023 04 01; 147(4):442-450.
    View in: PubMed
    Score: 0.534
  2. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 2016 Aug; 16(8):847-58.
    View in: PubMed
    Score: 0.335
  3. Management of recurrent head and neck cancer: recent progress and future directions. Drugs. 2011 Aug 20; 71(12):1551-9.
    View in: PubMed
    Score: 0.239
  4. Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol. 2011 Feb; 8(2):72-4.
    View in: PubMed
    Score: 0.230
  5. Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. Nat Rev Clin Oncol. 2010 Nov; 7(11):616-8.
    View in: PubMed
    Score: 0.226
  6. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw. 2008 Aug; 6(7):696-706.
    View in: PubMed
    Score: 0.193
  7. Concurrent chemoradiotherapy for head and neck cancer. Semin Oncol. 2004 Dec; 31(6):786-93.
    View in: PubMed
    Score: 0.150
  8. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004 Aug; 15(8):1179-86.
    View in: PubMed
    Score: 0.147
  9. Management of sarcomas of the head and neck. Curr Oncol Rep. 2004 Jul; 6(4):321-7.
    View in: PubMed
    Score: 0.146
  10. Overview of head and neck cancer. Cancer Treat Res. 2003; 114:1-13.
    View in: PubMed
    Score: 0.131
  11. Organ preservation for advanced head and neck cancer concomitant chemoradiation. Cancer Treat Res. 2003; 114:235-48.
    View in: PubMed
    Score: 0.131
  12. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs. 2001; 19(3):249-54.
    View in: PubMed
    Score: 0.114
  13. Couple-based communication intervention for head and neck cancer: a randomized pilot trial. Support Care Cancer. 2021 Jun; 29(6):3267-3275.
    View in: PubMed
    Score: 0.113
  14. Reduction of distant metastases in head and neck cancer with concomitant chemotherapy. J Clin Oncol. 2000 Sep 15; 18(18):3320-1.
    View in: PubMed
    Score: 0.112
  15. Benefits of chemotherapy in head and neck cancer. Lancet. 2000 Aug 26; 356(9231):767-8.
    View in: PubMed
    Score: 0.112
  16. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol. 2000 Jun; 11(6):721-8.
    View in: PubMed
    Score: 0.110
  17. Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled? Curr Opin Oncol. 2000 May; 12(3):221-8.
    View in: PubMed
    Score: 0.109
  18. Oral chemotherapy in head and neck cancer. Drugs. 1999; 58 Suppl 3:91-7.
    View in: PubMed
    Score: 0.100
  19. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
    View in: PubMed
    Score: 0.093
  20. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
    View in: PubMed
    Score: 0.076
  21. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
    View in: PubMed
    Score: 0.073
  22. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1391-8.
    View in: PubMed
    Score: 0.065
  23. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.055
  24. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Oct 01; 115(19):4504-13.
    View in: PubMed
    Score: 0.052
  25. Head and neck cancers. J Natl Compr Canc Netw. 2008 Aug; 6(7):646-95.
    View in: PubMed
    Score: 0.048
  26. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94.
    View in: PubMed
    Score: 0.048
  27. A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26.
    View in: PubMed
    Score: 0.046
  28. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
    View in: PubMed
    Score: 0.042
  29. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006 Jan; 28(1):64-73.
    View in: PubMed
    Score: 0.040
  30. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24.
    View in: PubMed
    Score: 0.040
  31. Head and neck cancers. J Natl Compr Canc Netw. 2005 May; 3(3):316-91.
    View in: PubMed
    Score: 0.039
  32. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
    View in: PubMed
    Score: 0.036
  33. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62.
    View in: PubMed
    Score: 0.036
  34. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
    View in: PubMed
    Score: 0.035
  35. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
    View in: PubMed
    Score: 0.034
  36. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
    View in: PubMed
    Score: 0.033
  37. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
    View in: PubMed
    Score: 0.029
  38. NCCN Practice Guidelines for Head and Neck Cancers. Oncology (Williston Park). 2000 Nov; 14(11A):163-94.
    View in: PubMed
    Score: 0.028
  39. Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer. Invest New Drugs. 2000 Aug; 18(3):261-3.
    View in: PubMed
    Score: 0.028
  40. Workshop report: organ preservation strategies in advanced head and neck cancer--current status and future directions. Head Neck. 1999 Dec; 21(8):689-93.
    View in: PubMed
    Score: 0.027
  41. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
    View in: PubMed
    Score: 0.025
  42. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
    View in: PubMed
    Score: 0.025
  43. Oral 5-FU alternatives for the treatment of head and neck cancer. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):35-8.
    View in: PubMed
    Score: 0.024
  44. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.